Stock Events

Stock Events

Inventiva 

€4.53
0
-€0.09-1.95% Friday 06:00

Statistics

Day High
4.53
Day Low
4.53
52W High
4.53
52W Low
4.53
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30MarExpected
Q4 2025
-0.94
-0.79
-0.63
-0.48
Expected EPS
-0.478612331353447
Actual EPS
-0.9439364269295695

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6IV.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Galapagos NV
GLPG
Mkt Cap1.91B
Galapagos NV focuses on developing novel modes of action, including fibrosis treatments, competing in the same therapeutic areas as Inventiva.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.92B
Madrigal Pharmaceuticals is involved in developing solutions for nonalcoholic steatohepatitis (NASH), a key area of focus for Inventiva.
Viking Therapeutics
VKTX
Mkt Cap3.97B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a competitor.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, competing with Inventiva's pipeline.
Agenus
AGEN
Mkt Cap152.06M
Agenus Inc. is focused on immuno-oncology but its interest in novel therapeutic approaches can indirectly compete with Inventiva's innovative treatments.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie has a diverse biopharmaceutical portfolio that includes research in fibrosis, making it a competitor.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a broad research portfolio that includes fibrosis and other areas relevant to Inventiva's interests.
Novartis
NVS
Mkt Cap297.35B
Novartis AG conducts extensive research in areas including fibrosis and metabolic diseases, overlapping with Inventiva's therapeutic areas.

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Show more...
CEO
Ms. Nazira Amra M.D.
Employees
84
Country
Malaysia
ISIN
FR0013233012

Listings

MU
DE
6IV.MU
STU
DE
6IV.STU
XETRA
DE
6IV.XETRA
STU
DE
6IVA.STU

0 Comments

Share your thoughts

FAQ

What is Inventiva stock price today?▼
The current price of 6IV.MU is €4.53 EUR — it has decreased by -1.95% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.
What is Inventiva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Inventiva stocks are traded under the ticker 6IV.MU.
Is Inventiva stock price growing?▼
6IV.MU stock has fallen by -0.33% compared to the previous week, the month change is a -15.42% fall, over the last year Inventiva has showed a +69.48% increase.
When is the next Inventiva earnings date?▼
Inventiva is going to release the next earnings report on September 25, 2026.
What were Inventiva earnings last quarter?▼
6IV.MU earnings for the last quarter are -0.94 EUR per share, whereas the estimation was -0.48 EUR resulting in a -97.22% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Inventiva have?▼
As of April 13, 2026, the company has 84 employees.
In which sector is Inventiva located?▼
Inventiva operates in the Health & Wellness sector.
When did Inventiva complete a stock split?▼
Inventiva has not had any recent stock splits.
Where is Inventiva headquartered?▼
Inventiva is headquartered in Daix, Malaysia.